Europe Sleep Apnea Devices Market Size and Share Analysis: Growth Trends, Industry Dynamics, and Forecast 2025–2033
Executive Summary
The Europe Sleep Apnea Devices Market is poised to grow from US$ 1.94 billion in 2024 to US$ 3.77 billion by 2033, at a CAGR of 7.68% during the forecast period. This growth is driven by increased awareness of sleep disorders, the rising prevalence of obstructive sleep apnea (OSA), aging populations, and rapid technological advancements in diagnostics and treatment devices.
1. Market Overview
What is Sleep Apnea and Why Are Devices Important?
Sleep apnea is a serious sleep disorder where breathing repeatedly stops and starts. Devices like CPAP, BiPAP, and advanced diagnostics such as PSG are critical in managing this condition. These devices ensure proper oxygen delivery, reduce complications such as heart disease, and significantly enhance patients’ quality of life.
2. Market Drivers
2.1 Rising Prevalence of Obstructive Sleep Apnea (OSA)
- According to studies, over 175 million European adults (~44% of the population) may suffer from sleep apnea.
- Contributing factors: obesity, aging population, sedentary lifestyles.
- Government reports (e.g., UK’s Future of an Older Population) forecast sharp increases in elderly populations by 2040, further boosting demand.
- France, for example, will see its elderly population rise from 15 million in 2012 to 24 million by 2060.
2.2 Technological Innovation and Miniaturization
- Next-generation portable CPAP/BiPAP machines, wearable devices, and AI-enabled monitors are transforming patient experiences.
- December 2024: Nyxoah SA launched a battery-free neurostimulator, Genio, in England—setting a precedent for innovation-led growth.
- Integration with IoT and smartphone apps increases device adherence and enhances remote patient monitoring.
2.3 Government Initiatives & Reimbursement Support
- Countries like Germany, UK, and France have strong reimbursement frameworks and national awareness programs.
- EU’s Open Strategic Autonomy (OSA) strategy is enabling investments in health-related technologies and infrastructure.
- NHS and EU-wide support for in-home diagnostic solutions is expanding device penetration.
3. Market Challenges
3.1 High Cost of Advanced Devices
- Despite reimbursement, CPAP/BiPAP machines and PSG systems remain costly—especially in Eastern Europe and rural regions.
- Out-of-pocket expenses deter many patients from diagnosis or ongoing therapy.
3.2 Underdiagnosis and Stigma
- Many patients remain unaware of their condition.
- Rural areas face limited access to sleep clinics or sleep specialists.
- Social stigma around using sleep masks or therapeutic devices hinders device adoption.
New Publish Reports
- Europe Functional Water Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- Europe Powder Dietary Supplements Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- Europe Confectionery Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- Europe Vitamin Fortified and Mineral Enriched Food & Beverage Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
4. Market Segmentation
4.1 By Type
A. Therapeutic Devices
- CPAP Devices
- Auto CPAP Devices
- BiPAP Devices
- Adaptive Servo-Ventilation (ASV)
B. Diagnostic Devices
- Polysomnography (PSG)
- Oximeter
- Actigraphy Monitoring
- Respiratory Polygraph
- Sleep Apnea Screening Devices
4.2 By End User
- Sleep Laboratories
- Clinics & Hospitals
- Home Care Settings / Individuals
5. Regional Market Analysis
5.1 United Kingdom
- Robust growth due to high awareness, aging population, and public reimbursement.
- Innovations in portable, patient-friendly CPAP and diagnostic devices fuel adoption.
5.2 Germany
- Largest market in Europe.
- December 2024: FDA approved Eli Lilly’s Zepbound to treat sleep apnea in obese adults—creating cross-industry growth (pharma + devices).
- Home-use smart devices with remote monitoring gaining popularity.
5.3 France
- Strong support for diagnosis and early treatment.
- July 2024: Inspire Medical Systems announced reimbursement for its implantable therapy.
- Expanding use of diagnostic labs and portable home-testing kits.
5.4 Italy
- Urban markets are adopting CPAP/BiPAP rapidly, but rural lag persists.
- December 2024: European Medicines Agency allowed label expansion of Mounjaro (tirzepatide), indirectly supporting sleep apnea management.
6. Device-Level Analysis
6.1 CPAP Devices
- Widely used, especially in Germany and the UK.
- Technological improvements (noise reduction, portability, Bluetooth connectivity) enhance patient compliance.
6.2 BiPAP Devices
- Suitable for patients with complex conditions like COPD or central sleep apnea.
- Market expanding as awareness of comorbid sleep apnea grows.
6.3 Oximeters
- Affordable and portable diagnostic tools.
- In-demand for at-home monitoring and follow-up care, especially in rural setups.
6.4 Screening Devices
- Polysomnography and portable monitors enable early-stage diagnosis.
- Widening availability due to increasing investment in sleep labs and home-use kits.
7. Healthcare Setting Analysis
7.1 Clinics & Hospitals
- Major hubs for diagnosis and therapy initiation.
- Benefit from collaborations with device manufacturers and public funding.
7.2 Homecare Settings
- Rising shift towards home-based care to reduce burden on hospitals.
- Supported by portable devices, remote monitoring, and app-integrated solutions.
8. Competitive Landscape
Key Companies (5-Point View)
| Company | Overview | Key Person | Recent Developments | Revenue & Product Portfolio |
| ResMed Inc. | Market leader in CPAP tech | CEO: Michael Farrell | Introduced smart CPAP platform | Strong revenue growth |
| Koninklijke Philips N.V. | Focus on sleep and respiratory care | CEO: Roy Jakobs | Expansion in portable devices | Broad product range |
| Fisher & Paykel Healthcare | Known for innovation | CEO: Lewis Gradon | Advanced humidification in devices | Revenue from therapeutic products |
| Nyxoah SA | Implantable neurostimulation devices | CEO: Olivier Taelman | Genio system launched in UK | Focused portfolio |
| Somnomed | Custom oral appliances | CEO: Neil Verdal-Austin | Partnered with European clinics | Dental-based sleep solutions |
9. Market Forecast (2025–2033)
| Year | Market Size (US$ Billion) |
| 2024 | 1.94 |
| 2025 | 2.09 |
| 2026 | 2.25 |
| 2027 | 2.42 |
| 2028 | 2.60 |
| 2029 | 2.80 |
| 2030 | 3.01 |
| 2031 | 3.23 |
| 2032 | 3.47 |
| 2033 | 3.77 |
10. Customization and Support
Renub Research offers:
- Up to 20% free customization
- Expanded country and segment-specific reports
- Competitive intelligence, strategy consulting, and trade analysis
- 1-year post-sale analyst support
Licensing Options:
- Dashboard (Excel): $2,490
- Single User PDF: $2,990
- Five User + Excel: $3,490
- Single User + Hard Copy: $3,490
- Corporate License (Multi User): $3,990
Contact Us
📞 USA: +1-478-202-3244 | 🇮🇳 India: +91-120-421-9822
📧 info@renub.com
🌐 www.renub.com
